20 RESULTS
Go to another page:
COMMENT I felt quite positive after having listened to the presentation. I understand better what happened in the futility analysis. I would like to see plasma p-tau concentrations in all subjects. I would also like to learn more about plasma neurofilament light ...
COMMENT This new aducanumab analysis is big and welcome news in Sweden, as well. With the proviso that there seems to be a certain amount of confusion regarding the futility analysis, the presented data appear appropriate and make sense. I am hopeful that this ...
COMMENT This is a great paper! For many years, it was hard to get a reliable amyloid biomarker signal from blood and many inconsistent results were published. Many researchers, including us, believed that peripheral production of Aβ (from platelets, hepatocytes, ...
COMMENT This study corroborates the strong association of APOE ε4 with amyloid buildup in the brain. Already at baseline the amyloid-positive group shows signs of neuronal impairment in the form of increased CSF concentrations of both total- and phospho-tau. ...
COMMENT We agree with Dr. Aisen that plasma NfL may potentially be useful as a biomarker for prescreening individuals who are selected for further testing before inclusion in early intervention trials. We think this is one of the most interesting possible future ...
COMMENT I definitely think this study strengthens the case for CSF neurogranin (Ng) as an AD biomarker. I think the expression of Ng in synapses, in conjunction with the increase in AD CSF, suggests that it may be a marker of synaptic degeneration in AD. I ...
COMMENT This is an interesting article, and we agree with its scientific argument. Bart de Strooper is right about the short half-life of semagacestat, and important aspects such as its rebound effect on CSF Aβ levels. Whether this explains the cognitive ...
COMMENT We read with interest the response by Netzer, Greengard, and colleagues. It is clear that we have different views not only on the biological effect of GSAP but also on Αβ (patho)physiology in general. There are some strong claims in the response, e.g., ...
COMMENT We welcome a discussion on the problem with irreproducibility of published research that we recently encountered, as outlined in the Alzforum news story. In this context, the recent editorial guidelines from Nature might represent one step to reduce this ...
COMMENT This is a very interesting study, again pointing to subcortical brain structures as the main sites of damage in mild traumatic brain injury. Now, we should specifically target living patients with progressive CTE using all the biomarkers we have to ...
COMMENT The association of traumatic brain injury and Alzheimer's disease has been up for discussion for many years, and prompted us to perform biomarker studies on the topic. We analyzed CSF samples from boxers to test the hypothesis that this group of ...
COMMENT When looking in PubMed, one sees that there is an exponential increase in the number of studies on biomarkers for AD, and the opportunities should be excellent for making meta-analyses on the topic. However, if one sets out to curate the literature, it ...
COMMENT These results are highly unexpected and in need of replication, but they are also very interesting in the light of what we currently know about Aβ homeostasis in several diseases of severe neuroinflammation, for example, bacterial meningitis, HIV ...
COMMENT This is a very interesting paper demonstrating that the neuropathology seen in some soldiers exposed to blast overpressure with clinical symptoms suggesting chronic traumatic brain injury is very similar to that of athletes with repetitive concussive head ...
COMMENT This is a thorough paper showing that CSF levels of VILIP-1 carry similar information as total tau. High CSF levels of the protein indicate intense neurodegeneration, which translates into rapid disease progression and cognitive decline. Whereas the ...
Go to another page:
